KERNAL BIOLOGICS
Kernal creates mRNA therapies to cure diseases like COVID and cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. Kernal won three awards from Amgen and NASA. With roots at MIT, Harvard and Big Pharma, the team previously built a successful Biotech company and has deep expertise in mRNA space.
KERNAL BIOLOGICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2016-08-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.kernalbio.com
Total Employee:
11+
Status:
Active
Contact:
+118576000762
Email Addresses:
[email protected]
Total Funding:
25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Lucy Therapeutics
Lucy Therapeutics is a biotech company providing effective treatments for neurological diseases start with the mitochondria.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Current Advisors List
Current Employees Featured
Founder
Investors List
HBM Genomics
HBM Genomics investment in Series A - Kernal Biologics
Amgen Ventures
Amgen Ventures investment in Series A - Kernal Biologics
Civilization Ventures
Civilization Ventures investment in Series A - Kernal Biologics
Hummingbird Ventures
Hummingbird Ventures investment in Series A - Kernal Biologics
Amino Collective
Amino Collective investment in Series A - Kernal Biologics
Julie McDermott
Julie McDermott investment in Seed Round - Kernal Biologics
SAV (Scale Asia Ventures)
SAV (Scale Asia Ventures) investment in Seed Round - Kernal Biologics
ISS National Lab
ISS National Lab investment in Grant - Kernal Biologics
The Boeing Company
The Boeing Company investment in Grant - Kernal Biologics
MassChallenge
MassChallenge investment in Non Equity Assistance - Kernal Biologics
Newest Events participated
Official Site Inspections
http://www.kernalbio.com Semrush global rank: 995.61 K Semrush visits lastest month: 34.66 K
- Host name: ec2-52-25-87-207.us-west-2.compute.amazonaws.com
- IP address: 52.25.87.207
- Location: Boardman United States
- Latitude: 45.8491
- Longitude: -119.7143
- Metro Code: 810
- Timezone: America/Los_Angeles
- Postal: 97818
More informations about "Kernal Biologics"
Kernal Biologics - Crunchbase Company Profile
Organization. Kernal Biologics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Kernalbio creates mRNA therapies that instruct specific cells on how to make their own โฆSee details»
About | Kernal Biologics
[email protected]. Synthetic biologists. Immunologists. Data scientists. Together, weโre making selective mRNA drugs to cure serious illnesses. Our goal is to improve patient experience by delivering medicines that will challenge the โฆSee details»
Kernalbio Company Profile 2024: Valuation, Funding & Investors
Kernalbio General Information Description. Developer of mRNA therapies designed to develop curative immunotherapies for cancers and COVID-19. The company's platform decreases โฆSee details»
Kernal Biologics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Kernal Biologics, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Kernal Biologics - Y Combinator
Jul 7, 2022 Kernal is creating mRNA 2.0 therapies that work in specific cells. Founded in 2016 by Yusuf Erkul, Cafer Ozdemir, and Burak YILMAZ, Kernal Biologics has 20 employees based โฆSee details»
Kernal Biologics, Inc. - Drug pipelines, Patents, Clinical trials
Explore Kernal Biologics, Inc. with its drug pipeline, therapeutic area, technology platform, 9 news, and 1 literature, Disease Domain:Neoplasms, Technology Platform ...See details»
Kernal Biologics - VentureRadar
Similar Companies: Strand Therapeutics USA Privately Held Strand Therapeutics is an early-stage biotechnology company genetically programming revolutionary therapies to improve the โฆSee details»
Kernal Bio - BIO International Convention | BIO
Jun 6, 2023 Kernal Bio is a venture-backed biotech company developing mRNA 2.0 immunotherapies. Kernal Bio mines massive translatome data to discover cell-specific โฆSee details»
Kernal Biologics Enters Development Phase Reaching Critical โฆ
Jul 22, 2021 In parallel, company expands team with seasoned drug developers and creates a business model to license a portion of its proprietary mRNA technology to global โฆSee details»
Kernal Biologics - workinbiotech.com
Kernal Biologics is developing mRNA therapeutics for diseases like COVID and cancer. mRNA therapeutics have much potential to deliver instructions to cells to produce therapeutic โฆSee details»
Kernal Biologics Enters Development Phase Reaching Critical โฆ
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Kernal Biologics, Inc. (Kernal Bio) โ an early-development-stage mRNA-technology company developing cancer therapeutics โฆSee details»
Kernal Biologics Presenting Results at the 9th Annual mRNA โฆ
Nov 9, 2021 Kernal Biologics, Inc. โ an early-development-stage mRNA-technology company developing cancer therapeutics designed to improve patientsโ survival rate and quality of life โ โฆSee details»
Kernal Biologics Announces $25M Series A Financing to Advance โฆ
Jul 7, 2022 Appoints Manfred Kraus, Ph.D. as Vice President of Research and Development. CAMBRIDGE, Mass., July 7, 2022 /PRNewswire/ -- Kernal Biologics, Inc. (Kernal Bio) โ a โฆSee details»
Kernal Biologics Presenting at the 12th mRNA Health Conference
Nov 11, 2024 Kernal Biologics to Present at the 12th International mRNA Health Conference. CAMBRIDGE, Mass., November 11, 2024/ -- Kernal Biologics, Inc. (Kernal Bio) โ a โฆSee details»
Kernal Biologics, Inc. (Kernal Biologics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ โฆ
Preclinical Data Support Use of Onco-selective mRNA LNPs as a Novel, Promising Modality for Immuno-oncology Applications CAMBRIDGE, Mass., July 20, 2023 /PRNewswire/ -- Kernal โฆSee details»
Kernal Biologics Presenting Results at the 9th Annual mRNA โฆ
Nov 9, 2021 Two presentations at the preeminent meeting of global mRNA industry and thought leaders include: 1) first publicly released outcomes from October 2020 NASA/International โฆSee details»
Kernal Biologics Announces Presentations at The International โฆ
Nov 9, 2022 Preclinical data demonstrates KR-335's ability to cause tumor regression, improved overall survival and complete responses across different murine tumor models as a โฆSee details»
Partnerships - Kernal Biologics
Partnerships Designed to Deliver. Leverage our proprietary technology to create and deliver mRNA therapeutics to address unmet needs in infectious, inflammatory, and cardiometabolic โฆSee details»
Science | Kernal Biologics
[email protected]. selective translation. our mrna selectively boosts cancer-fighting proteins in the diseased while minimizing off-target toxicity in the healthy: versatile delivery. most lnp โฆSee details»